In order to minimize the risks inherent in drug discovery, NeuroNova’s strategy is to balance its internal research efforts with revenue-generating collaborations and license agreements with leading pharmaceutical and biotechnology companies.

NeuroNova is building a diversified pipeline of preclinical and clinical stage projects in order to ensure portfolio depth and sustainability over time. As the projects progress through the drug development pipeline, the Company intends to realize value by out-licensing and partnering with other biopharmaceutical companies. In some cases, NeuroNova may retain regional marketing rights for its products in order to benefit from sales revenue to support its R&D.

NeuroNova is also set to gain near-term revenues from technology platform collaborations with selected pharmaceutical companies interested in harnessing NeuroNova’s experience and capabilities in the area of therapeutic neurogenesis.

We believe that working in partnership with other biopharmaceutical companies will result in a mutually beneficial relationship that can maximize the opportunities for both parties involved.

For more information, please contact Ulf Ljungberg, President and CEO This e-mail address is being protected from spam bots, you need JavaScript enabled to view it